Fort Myers-based NeoGenomics Inc. has revised its outlook for fourth-quarter earnings.
The company now expects revenues in the range of $12 million to $12.5 million for the quarter. That’s up from its original estimate of $11.4 million to $12 million, which it released on Oct. 19.
The company expects to be profitable in the fourth quarter, with earnings of up to 1 cent a share.
Doug VanOort, the company’s chairman and CEO, said, “We experienced strong year-over-year revenue growth in both October and November, and our rate of growth has continued to accelerate. This growth is broad-based, and is the result of a variety of growth initiatives we have made over the last eighteen months.”
The company offers genetic testing, focused on the diagnosis of cancer.